Loading page
What we know about this company
Open this Idea →Centrus Energy Corp.
Watching · below 8/10
our belief 6/10 · confidence score 55/100
Our longer-term business view, not a prediction for this week.
May rise over the next year. Open for the simple explanation.
Why we are waiting
Our belief is below the 8/10 level needed for a strong Idea.
Next check: Keep it in background research until our belief reaches 8/10.
Research conviction is below the 8/10 level needed for a high-conviction idea. DOE task-order cadence, Piketon and Oak Ridge execution, capital intensity, and offtake conversion remain unresolved.
The research view is still too uncertain at 6/10 to treat this as a current opportunity.
View unchanged Sep 2, 2026 · research strength 6/10 — full saved wording is in the research history
$152.31
last session
Quarterly results in 60 days · Nov 11 · Estimated date
Centrus is the only American-owned company that enriches uranium into fuel for nuclear power plants — and the only U.S. company licensed to make the special higher-enriched fuel (called HALEU) that all the new small modular reactors need. It does make money today: about $176 million in the most recent quarter and roughly $39 million of adjusted profit, with $1.87 billion of cash in the bank. But the exciting part — building a big new enrichment plant in Ohio — will not deliver its first commercial fuel until around 2029-2030. In 2026 the government signed a $900 million contract to help pay for that plant, and the SMR company X-energy signed a supply deal with upfront payments, which together cover a chunk of the build cost without Centrus having to sell more shares. The one thing that has to go right is finishing that plant roughly on time; the one thing that could go wrong is the plant slipping two or three years or the French competitor Orano getting its own new U.S. plant running first.
Loading company numbers
Loading latest quarterly results
Loading ownership and market expectations
Supplemental SEC filing context loads independently from the company evidence above.
Checking the newest complete filings from the large investors we follow. The rest of this page is ready while these delayed reports load.
Aug 12, 2026
At 6/10 this is below the 8/10 level required to publish it as a strong Idea. The research is still saved:
Long, conviction 7. The 2026 signings (DOE $900M, X-energy definitive, Oklo JV, $4.5B backlog) materially de-risk the enrichment monopoly thesis, but the cash-flow payoff remains 2029-2030 and the stock is 60% off its 52-week high — a genuine long-term hold, not a near-term catalyst play.
Loading research history
1 check left
Current active Idea · Record saved Aug 11, 2026 · check date unavailable. The original research wording and date checks stay available inside.
These events and risks belong to TickerYou’s current Idea.
An event can change what investors believe. A risk shows how our research could be wrong.
Watch for a company announcement or filing that confirms or moves this date.
Expected from Centrus Energy (LEU) Earnings Date & Report - Investing.com · Aug 6, 2026
No eligible material change since the previous company check.
A company check updates what we know. It does not by itself turn this company into a current opportunity.
1 older quarterly-results date is hidden because a newer company check is shown above.
Computed by TickerYou from 1254 completed daily closing sessions supplied by Yahoo Finance, through Sep 10, 2026. The Sep 11, 2026 quote-session candle was excluded because a delayed feed cannot prove it was final. No company fundamentals enter this reading.
The price has been trending down across both the medium and longer term.
Price movement can help with timing and can warn when the market disagrees with our Idea. It does not tell us what the business is worth.
Watch whether the close can recover above the 50-session average at $174.99; the 200-session average at $209.51 is the slower reference.
Last closing price
$165.87
Sep 10, 2026
Average price over 20 trading days
$180.25
Close is 8.0% below this average
Average price over 50 trading days
$174.99
Close is 5.2% below this average
Average price over 200 trading days
$209.51
Close is 20.8% below this average
Recent price speed
43.7 · balanced
A 14-day speed reading; lower than 30 is low and higher than 70 is high
Is the trend speeding up?
Below signal
Shows whether the shorter trend is pulling ahead of or behind the longer one
The moving averages are simple averages over exactly 20, 50, and 200 daily trading sessions. RSI uses Wilder's 14-session smoothing; a flat series is neutral at 50. MACD uses 12- and 26-session exponential averages with a 9-session signal. A window is never shortened when history is missing. Every comparison uses the final dated daily close—not an intraday quote—so all figures share one observation boundary. A candle dated to an active delayed-quote session is excluded because it may still be changing. These are trend and momentum references, not a Buy/Sell score.
Each quarter is named by the fiscal quarter the company itself reported — the label its release used and its consensus estimate was quoted against — and by the month that quarter ended, taken from the filer's own XBRL period boundaries. A fiscal year need not follow the calendar, so Apple's Q2 runs January to March; naming the quarter end keeps that true in both calendars, and no quarter number is ever inferred from a date. Quarterly financials beside this card names the same quarter the same way. TickerYou takes the figures from the release and its filing; every word, sign and percentage is calculated by the app from those stored numbers. A post-release reaction appears only with the stored first-close measurement stamp; otherwise the card says the window is not established and computes no divergence. EPS here is on the basis consensus quotes — adjusted for most US names — so it can legitimately differ from the GAAP figure in Quarterly financials. Rows marked [backfilled] were confirmed from archived coverage after the fact — a lower evidence tier than live capture, and labelled so.
Q2 FY2026 · Jun 2026: EPS beat the stored consensus estimate, while revenue beat the stored consensus estimate. No post-release price reaction is asserted because its stamped measurement window is not established.
A surprise shows how the release differed from expectations, not whether the business is good or the thesis is right. The price reaction shows repricing, not its cause.
Watch whether the next comparable release confirms the result; one beat or market move does not establish a durable trend.
Quarter ended Jun 30, 2026 · Reported Aug 5, 2026 · stock move after results · not shown
[backfilled] The quarter delivered $176.1M revenue (+14% YoY) on the strength of a $900M DOE HALEU enrichment award; management raised full-year guidance to $450–500M revenue, grew total backlog to $4.5B through 2040, and reported adjusted net income of $38.7M — though GAAP net income fell to $16.8M YoY due to non-cash adjustments inherent to uranium enrichment accounting.
Quarter ended Mar 31, 2026 · Reported May 5, 2026 · stock move after results · not shown
[backfilled] Adjusted diluted EPS of $1.05 beat the $0.33 consensus sharply, driven by $17M of growth costs excluded from the adjusted figure and a 47% surge in Technical Solutions revenue; total revenue of $76.7M edged past the estimate; Centrus raised full-year 2026 revenue guidance to $450M–$500M and highlighted a potential $900M+ DOE HALEU award.
Quarter ended Dec 31, 2025 · Reported Feb 10, 2026 · stock move after results · not shown
[backfilled] A delayed Russian LEU shipment (pushed into 2026 by a logistics issue) compressed Q4 gross margin sharply, driving EPS well below consensus; revenue came in roughly on target; the company ended 2025 with $2.0B unrestricted cash, a freshly awarded $900M DOE HALEU contract, and issued 2026 guidance.
Quarter ended Sep 30, 2025 · Reported Nov 5, 2025 · stock move after results · not shown
[backfilled] Centrus posted adjusted EPS of $0.19 against a $0.20 Zacks consensus; SWU deliveries held under long-term U.S. government contracts, HALEU demonstration at Paducah continued, and full-year guidance was reaffirmed.
Computed from SEC filings — never model output. Each quarter is named by the fiscal quarter the company itself reported and the month that quarter ended, through the same resolver the Earnings card beside this one uses; where no release established a fiscal label, the quarter is named by its end alone rather than by a quarter number guessed from the date. EPS is GAAP diluted, as filed, so it can legitimately differ from the adjusted figure in the Earnings card (consensus is quoted adjusted). Y/Y compares the same fiscal quarter a year earlier; a comparison that cannot be made honestly is an em-dash that says why.
Q2 FY2026 · Jun 2026: Revenue grew 14.0% year over year; net income fell 41.9% year over year; and net profit margin was 9.5%, down 9.2 percentage points.
Comparing the same fiscal quarter a year earlier controls for seasonality. Revenue direction and margin direction together show whether sales are translating into profit, but one quarter is evidence—not a complete thesis.
Watch whether the next comparable quarter restores margin; revenue growth with falling margin can be lower-quality growth.
1M
3M
6M
1Y
Computed from SEC filings — never model output. Blank means it cannot be computed honestly.
Revenue grew 8.5% versus the comparable filing period, while operating margin was 1.6%.
Revenue shows whether demand is expanding, while operating and free-cash-flow margins show how much of those sales becomes profit and cash. Net cash or debt affects how resilient that result is.
Watch whether the next comparable filing confirms the revenue direction and whether operating and cash-flow margins hold or improve.
Every figure comes from an SEC filing and carries the day it was measured. Nothing here is estimated.
A year-over-year share-count conclusion is not established: no count newer than 2022-03-01.
Without two comparable filed counts, the app cannot say whether existing owners gained or lost percentage ownership.
Watch for two comparable filing cover pages before interpreting dilution or ownership-slice change.
Total share count — not known yet
no count newer than 2022-03-01
The newest undimensioned cover-page count in the SEC feed for this filer is 13,673,933 shares, counted 2022-03-01 — 4.5 years ago. An active filer puts a fresh count on the cover of every 10-Q and 10-K, so a series that has gone more than 15 months without one has stopped, and the last figure in it does not describe today. The usual cause is a company with more than one share class: the modern cover page tags each class separately, and this feed exposes only the untagged total, so the combined series simply ends. Showing that figure as the share count — or multiplying it by today's price for a market cap — would not be a stale number, it would be a wrong one.
No bar is drawn: with no total share count there is nothing to draw a proportion of.
| (USD) | Q2 FY2026Quarter ended Jun 2026 | vs last year |
|---|---|---|
| Revenue | $176.10 M | |
| Profit after costs | $16.80 M | |
| Profit per share | 0.77 | |
| Profit margin | 9.5% |
† derived: the fiscal year minus its three reported quarters — no 10-K reports a Q4 figure directly. For EPS this assumes per-share figures add across the year.
| Quarter | Revenue | Y/Y | Net income | Margin |
|---|---|---|---|---|
| Q1 FY2026 · Mar 2026 | $76.70 M | $10.00 M | 13.0% | |
| Q4 FY2025 · Dec 2025 | $146.20 M † | $18.00 M † | 12.3% | |
| Q3 FY2025 · Sep 2025 | $74.90 M | $3.90 M | 5.2% | |
| Jun 2025 | $154.50 M | $28.90 M | 18.7% | |
| Mar 2025 | $73.10 M | $27.20 M | 37.2% | |
| Dec 2024 | $151.60 M † | $52.50 M † | 34.6% | |
| Sep 2024 | $57.70 M | $-5.00 M | -8.7% | |
| Jun 2024 | $189.00 M | $30.60 M | 16.2% |
— no count newer than 2022-03-01
measured Jun 30, 2025, 14 months ago — from the 10-K filed Feb 11, 2026
Market value of shares held by non-affiliates under the SEC filing definition. This is a dollar amount, not a share count. It is never converted into one to fill the line above.
Not researched yet. Release dates, tranche sizes, the shares issued at IPO and the insider breakdown are prose in the prospectus and in 8-Ks, with no XBRL tag to read them from. They appear here once TickerYou research can quote the source clause behind each figure—never estimated in the meantime.
Append-only company checks, newest evidence first. Evidence dates come from frozen research cutoffs; older rows without a cutoff are labelled by publication time instead. Multiple checks are preserved, never silently merged into one conclusion.
No eligible material change since the newest prior sweep. The 3m focus remains the expected November Q3 update; the 1y case still depends on DOE-backed HALEU execution, X-energy/offtake conversion and scale-up timing.
2026-11-11 (expected, not company-confirmed) for Q3 2026 earnings reporting date was estimated by Investing.com.
Checked Centrus August 5 EDGAR 8-K for the latest quarterly results filing.
Checked Centrus August 6 EDGAR 10-Q for detailed quarterly filing baseline.
Checked Centrus August 6 EDGAR 8-K for X-energy supply agreement disclosure.
Checked Centrus August 18 EDGAR 8-K for recent governance and compensation disclosure.
No material change since the 2026-08-28 prior sweep. The 3m focus remains the expected November Q3 update; the 1y case still depends on DOE-funded HALEU execution, X-energy/offtake prepayments, and Piketon/Oak Ridge scale-up risk.
2026-11-11 (expected, not company-confirmed) after market for Q3 2026 earnings reporting date was listed by Investing.com.
No material change from the late-August prior sweep. The 3m setup is the expected November Q3 update, while the 1y thesis still rests on HALEU funding execution, offtake conversion, and Piketon/Oak Ridge scale-up risk.
2026-11-11 (expected, not company-confirmed) after market for Q3 2026 earnings reporting date was listed by Investing.com for Centrus Energy.
Evidence checked Aug 26, 2026 · 2 recorded assessments
No material change since the newest prior sweep at 2026-08-26T17:39:11.92+00:00. The 3m setup is the expected November Q3 update; the 1y case still rests on HALEU funding execution, offtake, backlog conversion, and capital intensity.
2026-11-11 (expected, not company-confirmed) earnings reporting date was listed by Investing.com for Centrus Energy's next earnings report.
Evidence checked Aug 24, 2026 · 2 recorded assessments
No material change since the newest prior sweep at 2026-08-24T18:26:22.472+00:00. The 3m focus is Q3 earnings and execution disclosures; the 1y case still rests on DOE/X-energy-backed HALEU scale-up execution.
Checked LEU next earnings calendar status for Q3 2026
Published Aug 19, 2026 · 2 recorded assessments
Fundamentals strengthening into the U.S. enrichment thesis: Q2 revenue up YoY, a ~$900M DOE HALEU award, a new prepaid X-energy contract, and a ~$3B contingent backlog. The story is now execution on Oak Ridge centrifuge capacity (first new machine targeted year-end 2026); backlog is contingent, so conversion to firm cash flow is the thing to watch. Constructive, catalyst-rich.
Published Aug 12, 2026 · 3 recorded assessments
Centrus posted a clean Q2: record $4.5B backlog through 2040, a $900M non-dilutive DOE task order to fund the centrifuge build-out, and back-to-back HALEU commercial off-takes from Oklo and X-energy in the same reporting period. It remains the sole U.S. HALEU producer and is piling up prepayment-backed contracts ahead of first centrifuge completion at Oak Ridge, expected before year-end. Near-term GAAP profit is compressing under operating cost inflation, and analysts trimmed targets accordingly, but the long-dated backlog and government co-funding make the build credible. First Oak Ridge centrifuge is the next material catalyst.
Checked Centrus issuer news page; latest visible release was August 24, outside the last-five-day window.
Checked Centrus August 5 earnings 8-K directly on EDGAR for the latest results filing.
Checked Centrus August 6 10-Q directly on EDGAR for quarterly report and HALEU contract exhibits.
Checked Centrus August 6 8-K directly on EDGAR for the X-energy LEU and HALEU supply announcement.
Checked Centrus August 18 8-K directly on EDGAR for executive incentive grant disclosure.
Checked Centrus issuer news page for last-five-day company news and Piketon updates.
Not fundamental on its own: the issuer page describes stakeholder visibility around Piketon and the domestic nuclear fuel supply chain, but it does not disclose a new contract, funding award, capacity milestone, or guidance change.
source ↗Checked Centrus August 5 earnings 8-K directly on EDGAR for the latest results filing.
Checked Centrus June-quarter 10-Q directly on EDGAR for the latest quarterly filing baseline.
Checked Centrus August 18 compensation 8-K directly on EDGAR for executive grant disclosures.
Checked Centrus August 24 Piketon facility visit release for any new funding, contract, or expansion milestone.
The release reinforces state and local support for the Piketon expansion and cites expected construction and operating jobs, but it does not announce a new contract, funding award, or capacity milestone beyond the existing expansion narrative.
source ↗Checked Centrus August 18 8-K directly on EDGAR for recent leadership or compensation-related disclosure.
Checked Centrus August 6 10-Q directly on EDGAR for quarterly financial and contract disclosure.
Checked Centrus August 6 8-K directly on EDGAR for the X-energy related other-event filing.
Checked Centrus August 5 earnings 8-K directly on EDGAR for latest results filing baseline.
No material thesis change since the newest prior sweep at 2026-08-24T19:50:31.144+00:00. The 3m focus remains the expected November Q3 earnings update; the 1y case still depends on funded HALEU execution, backlog conversion, and avoiding dilution or schedule slippage.
2026-11-11 (expected, not company-confirmed) earnings reporting date was estimated by TipRanks from past reporting schedules.
Checked Centrus August 18 8-K directly on EDGAR for recent governance and compensation filings.
Checked Centrus Q2 2026 10-Q directly on EDGAR for the latest quarterly filing baseline.
Checked Centrus August 6 8-K directly on EDGAR for X-energy supply-agreement exhibit context.
Checked Centrus August 5 earnings 8-K directly on EDGAR for latest results filing.
Checked Benzinga LEU news list for recent company and uranium-sector headlines after the prior sweep.
Not fundamental from the opened source because it does not document a new contract, funding award, balance-sheet change, or guidance update.
source ↗Checked LEU recent SEC filings directly on EDGAR
Checked Centrus company news-release archive for recent company announcements
No new material company release found after the prior sweep; the current file still points to an improving but execution-heavy enrichment thesis, with Q3 earnings on November 11 as the next 3m catalyst.
Checked LEU next earnings date and earnings status from a live earnings-calendar source
Checked Centrus August 5 earnings 8-K directly on SEC EDGAR
Checked Centrus June quarter 10-Q directly on SEC EDGAR
Checked Centrus X-energy supply agreement 8-K directly on SEC EDGAR
Checked Centrus August 18 governance 8-K directly on SEC EDGAR
Checked Centrus company news releases for recent company-published news
Adds contracted, prepaid demand to the enrichment backlog and de-risks the domestic capacity build-out — directly changes future earnings power.
source ↗Revenue growth plus a large government award and a $3B contingent backlog materially expand the visibility of long-term cash flows in the enrichment franchise.
source ↗LEU is the clearest domestic HALEU enrichment play with hard contracted evidence: $900M DOE award, $4.5B total backlog with all contingencies removed, X-energy supply pact, and Q2 EPS nearly double consensus. First centrifuge at Oak Ridge expected 2026. Revenue is real at $176M/quarter — not speculative. 1y horizon conviction is high if energy-security policy framework holds.
First centrifuge completion at Oak Ridge would be the first domestic enrichment capacity milestone in decades; CEO confidence that the supply chain has 'come together' validates the $900M DOE contract execution timeline.
source ↗New private-sector contracted revenue starting 2030 diversifies Centrus beyond the DOE contract directly into advanced reactor fuel supply — a structurally durable demand source independent of government budget cycles.
source ↗Analyst price target revision following known results; does not change the underlying earnings trajectory.
source ↗Adds another commercial HALEU off-take to the backlog with customer prepayments as non-dilutive capital; validates Centrus's first-mover position as the only U.S. HALEU enricher and deepens the $4.5B revenue pipeline.
source ↗Minor post-earnings target trims reflecting cost inflation concerns; neither changes the structural HALEU supply thesis and both firms remain constructive.
source ↗Centrus is executing precisely on its nuclear-fuel monopoly thesis. The $900M DOE HALEU award combined with the X-energy commercial deal brings the enrichment backlog to $4.5B — a multi-year earnings floor. Q2 beat on both lines. The only risk is timing: HALEU deliveries start 2030 and near-term earnings are lumpy. Strong long-term hold with upside as SMR demand accelerates; next catalyst is Q3 delivery volumes and any additional HALEU offtake agreements.
Revenue grew 14% YoY and EPS cleared consensus by ~8%; the $900M DOE HALEU award and $4.5B total backlog confirm durable revenue visibility through the decade.
source ↗Locks in a new commercial customer for HALEU — still a nascent market — with prepayments that reduce financing risk for capacity expansion; diversifies revenue beyond DOE government contracts.
source ↗Analyst target revision following Q2 beat and HALEU contract news; price commentary, not a change in fundamentals.
source ↗Centrus is at the center of US nuclear fuel security in a way no other public company can replicate — it operates the only domestically enriching HALEU cascade in America, now anchored by a $900M DOE commercial contract and a new X-energy supply agreement on top of a $4.5B total backlog. Q2 2026 beat on both revenue and EPS, full-year guidance of $450–$500M is credible, and the PT is moving toward $188. The thesis is intact and executing. Key risks remain: (1) timing and capex on the $560M Oak Ridge centrifuge expansion needed to scale HALEU supply to 5+ MTU/year by the late 2020s, and (2) customer concentration — X-energy and the DOE together are effectively the entire near-term revenue base. With the stock approaching the revised analyst PT, near-term upside is limited until Oak Ridge milestones de-risk the production ramp. Long-term, if HALEU becomes standard fuel for the emerging SMR fleet, Centrus is the unavoidable chokepoint.
Confirms the enrichment business is converting its $4.5B backlog into revenue ahead of schedule; LEU segment alone was $153.4M, full-year guidance of $450–$500M implies acceleration in H2 and validates commercial-scale production capacity.
source ↗Adds a new long-term commercial customer for both enrichment products, extending Centrus's backlog beyond the DOE contract and confirming dual-use commercial demand for HALEU; X-energy prepayments improve near-term cash flow and reduce execution risk on the ACP expansion.
source ↗PT revision reflects stronger backlog assumptions post-Q2; adds no new fundamental information — pure analyst reaction.
source ↗Complete SEC 13F filings only. These delayed reports show filed share amounts, not a manager’s full portfolio, intent, or a proven trade.
3 of 14 recent complete filings report ordinary shares. Compared with the prior report: 2 with more shares and 1 with fewer shares.
A large, repeated position can support a research story, but these filings arrive late and do not show an investor’s full portfolio or reason for owning the stock.
Look for the same investor to keep a meaningful position across several reports.
No numeric score or recommendation is made from these delayed filings. They are one piece of background evidence, not a buy or sell signal.
14 current complete filings of 16 tracked managers. 2 investors have only an older filing and are left out of this current view. Current holding dates span Mar 31, 2026 to Jun 30, 2026.
LEU is 0.06% of Renaissance Technologies's disclosed portfolio ($47.08 M). Holdings as of Jun 30, 2026. Reported in 3 consecutive quarters.
LEU is 0.01% of Bridgewater Associates's disclosed portfolio ($3.48 M). Holdings as of Jun 30, 2026. Reported in all 6 quarters we can see.
LEU is 0.00% of Citadel Advisors's disclosed portfolio ($8.82 M). Holdings as of Jun 30, 2026. Reported in all 2 quarters we can see.
Market-neutral / multi-strategy: Citadel often reports shares, calls, and puts at the same time. These rows show reported exposure, not a simple bullish or bearish bet.
Citadel Advisors (Ken Griffin) reports a PUT option ($46.45 M). The filing does not prove whether it is a bet or a hedge, so options never count as ordinary shares above.
Citadel Advisors (Ken Griffin) reports a CALL option ($56.10 M). The filing does not prove whether it is a bet or a hedge, so options never count as ordinary shares above.
2 newly or higher reported, 1 lower reported. Reported amounts only; corporate actions are not normalized.
Reported by 3 of 14 managers with a current filing; at least 0.5% of disclosed 13F value for 0.
Largest reported position: Renaissance Technologies at 0.06% of disclosed 13F value ($47.08 M).
Across 6 quarters of stored filings: 6 newly or higher comparisons, 6 lower or absent, 0 unchanged, across 4 managers. Corporate actions are not normalized.
No numeric score is shown: filing comparisons are not adjusted for splits or other corporate actions, so reported changes cannot be treated as trades.
13Fs can arrive up to 45 days after quarter end. They omit short positions, cash, and securities outside the SEC's 13(f) list. Higher, lower, new, and absent describe filed share amounts, not proven purchases or sales; splits and other corporate actions are not normalized. This is context for a thesis, never a call by itself.